勃起不全治療薬の世界市場：分析 - 薬剤タイプ別、投与経路別、流通チャネル別、地域別、予測（～2030年）

世界の勃起不全治療薬の市場規模は、2023年に28億3,000万米ドルに達し、予測期間中にCAGR 8.8％で成長し、2030年には51億1,000万米ドルに達すると予測されています。

勃起不全（ED）治療薬は、性交渉に十分な勃起が得られない、または維持できない状態を治療するために設計された薬です。ED治療薬は、陰茎への血流を増加させ、性的刺激時に勃起しやすくすることで効果を発揮します。一般的なED治療薬には、シルデナフィル（バイアグラ）、タダラフィル（シアリス）、バルデナフィル（レビトラ）などがあり、これらはホスホジエステラーゼ5型（PDE5）阻害薬と呼ばれる種類の薬剤に属します。これらの薬剤は通常経口投与され、ED治療に革命をもたらし、何百万人もの男性に性的パフォーマンスと生活の質を高めるための信頼できる効果的な解決策を提供しています。

Clinical Epidemiology and Global Health Journalによると、勃起不全は世界で1億5,000万人以上の男性に影響を及ぼしており、2025年にはその数は3億2,200万人にまで増加すると予測されています。米国国立衛生研究所（NIH）によると、2022年、勃起不全（ED）は米国では非常に一般的な疾患であり、毎年約3,000万人の男性が罹患しています。

高まる認識と受容

勃起不全市場におけるED治療薬の認知度と受容度の高まりは、EDが医学的疾患として認知され、正常化しつつあることを意味します。社会的な態度が進化し、性の健康に関する会話がよりオープンになるにつれて、個人がEDの治療を求める可能性が高まっています。このような認識の変化は、ED治療薬が合法的な解決策であることを受け入れ、需要を高めることにつながります。さらに、教育キャンペーンや広告活動は、利用可能な治療オプションについての認識を広める上で重要な役割を果たしており、市場の成長をさらに後押ししています。

規制上のハードル

勃起不全治療薬市場における規制上のハードルは、主に厳しい承認プロセスと保健当局による継続的な監視に起因します。これらのハードルには、安全性と有効性を確立するための厳格な臨床試験や、表示・広告規制の遵守が含まれます。さらに、潜在的な副作用や他の薬との相互作用に対する懸念も、規制の複雑さを助長しています。また、特許保護や知的財産権に関する紛争によって市場参入が遅れることもあります。このような規制上のハードルを乗り越えるには、多大なリソースと専門知識が必要となるため、ED治療薬市場における競争とイノベーションが抑制される可能性があります。

医薬品開発の革新

勃起不全市場における医薬品開発の革新は、製薬会社と患者の双方に有望な機会をもたらします。血管の問題、神経障害、ホルモンバランスの乱れなど、EDの根本的な原因の解明が進めば、研究者は薬物介入のための新たな経路をターゲットにすることができます。この技術革新は、バイアグラやシアリスのような現在の薬に比べ、副作用の少ない、より効果的で安全な治療法の選択肢につながる可能性があります。さらに、個別化医療におけるブレークスルーは、個々の患者の特性に基づいてオーダーメイドの治療を可能にし、有効性と患者の満足度を高める可能性があります。

特許切れ

勃起不全治療薬市場における特許切れの脅威とは、バイアグラ、シアリス、レビトラのような主要医薬品の独占権の喪失が迫っていることを指します。これらの特許が切れると、ジェネリック医薬品が市場に参入する可能性があり、激しい競争と先発ブランドの価格低下を招く。これは、これらの医薬品の独占的権利を保持してきた製薬企業の収益源に大きな影響を与える可能性があります。さらに、ジェネリック医薬品は低価格であることが多く、消費者のブランド品離れを誘引します。このような競合シナリオは、競争が激化する中で市場シェアと収益性を維持するという課題を企業に突きつけることになります。

COVID-19の影響：

COVID-19の大流行は、勃起不全（ED）治療薬市場に大きな影響を与えました。移動が制限され、ヘルスケアの優先事項がパンデミック対策にシフトする中、ED治療薬の需要は変動しました。最初の封鎖は医師の受診や処方の減少につながったが、その後、規制が緩和され、遠隔医療が普及するにつれて需要が増加しました。家屋規制のため、新婚夫婦やその他の親密な活動が大幅に増加し、その結果、ED治療薬を含む性交に関連するものが増加しました。経済の不確実性も、ED治療薬のような非必需品への消費者の支出に影響を与えました。

予測期間中、バイアグラ（クエン酸シルデナフィル）セグメントが最大となる見込み

ED治療薬市場におけるバイアグラ（クエン酸シルデナフィル）セグメントの成長は、いくつかの要因によるものと考えられます。バイアグラはED治療薬のパイオニア的存在であり、消費者の間で強いブランドプレゼンスと信頼を確立しました。バイアグラのED治療における有効性は確立されており、医師や患者に広く採用されています。クエン酸シルデナフィルのジェネリック医薬品が入手可能になったことで、手頃な価格で入手しやすくなり、市場の成長をさらに後押ししています。さらに、継続的な研究開発努力により、革新的な製剤や投与方法が生み出され、市場の裾野が広がっています。さらに、EDに対する意識の高まりと、治療を求めることの非人格化が、バイアグラを筆頭とするED治療薬市場全体の拡大に寄与しています。

外用薬セグメントは予測期間中に最も高いCAGRが見込まれる

外用薬セグメントの成長は、外用製剤が提供する利便性と慎重さが、非侵襲的な治療オプションを求める消費者にアピールしていることに起因しています。製剤技術の進歩により、外用薬の有効性と吸収率が改善され、その効果が高まっています。患者とヘルスケア提供者の双方における局所治療に対する認識と受容の高まりが、市場の需要を促進しています。さらに、全身的な副作用が少なく局所的な治療を好む傾向が外用薬の採用を後押しし、同分野の持続的拡大に寄与しています。

最大のシェアを占める地域

北米地域は、EDに対する意識の高まりと治療選択肢の増加により、勃起不全治療薬市場で大きな成長を遂げています。医療技術の進歩により、より効果的で安全なED治療薬が開発され、消費者の信頼と支持を高めています。さらに、北米では高齢化が進んでおり、ストレスや座りがちな生活習慣などのライフスタイル要因もED患者の増加に寄与しているため、治療需要が高まっています。同地域の強固なヘルスケアインフラと有利な償還政策は、ED治療薬へのアクセスを容易にし、市場成長をさらに促進しています。

CAGRが最も高い地域：

アジア太平洋は、いくつかの要因により顕著な急成長を遂げています。性の健康に対する意識の高まり、生活習慣病の罹患率の上昇、医療サービスへのアクセスの拡大などが主な促進要因です。さらに、性の健康についてよりオープンに議論する文化的シフトがスティグマを減らし、個人が治療を受けることを奨励しています。さらに、革新的な治療オプションの利用可能性が市場の成長を促進しています。アジア太平洋は人口が多く、ヘルスケアインフラが整備されていることから、勃起不全治療薬市場のさらなる拡大に向けて大きなチャンスをもたらしています。

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の勃起不全治療薬市場：薬剤タイプ別

• バイアグラ（クエン酸シルデナフィル）
• アバナフィル（ステンドラ/スペドラ）
• シアリス（タダラフィル）
• ヘルバ（炭酸ロデナフィル）
• レビトラ/スタキシン（バルデナフィル）
• エムビックス（ミロデナフィル）
• ビタロス（アルプロスタジル）
• ザイデナ（ウデナフィル）
• その他の薬剤タイプ

第6章 世界の勃起不全治療薬市場：投与経路別

• 経口薬
• 外用薬
• 注射

第7章 世界の勃起不全治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 世界の勃起不全治療薬市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイリング

• Abbott Laboratories
• Allergan plc
• Apricus Biosciences, Inc.
• Bayer AG
• Cristalia Produtos Quimicos Farmaceuticos Ltda.
• Dong-A Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• Endo International plc
• Futura Medical plc
• Ion Channel Innovations, LLC
• Johnson & Johnson
• Meda Pharmaceuticals Inc.
• Metuchen Pharmaceuticals, LLC
• Pfizer Inc.
• Regent Pacific Group Limited
• Sandoz International GmbH
• Sinil Pharmaceutical Co., Ltd.
• SK Chemicals Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• VIVUS, Inc.

List of Tables

• Table 1 Global Erectile Dysfunction Drugs Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
• Table 4 Global Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
• Table 5 Global Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
• Table 6 Global Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
• Table 7 Global Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
• Table 8 Global Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
• Table 9 Global Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
• Table 10 Global Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
• Table 11 Global Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 12 Global Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 13 Global Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
• Table 14 Global Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
• Table 15 Global Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
• Table 16 Global Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 17 Global Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 18 Global Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 19 Global Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 20 North America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 22 North America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
• Table 23 North America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
• Table 24 North America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
• Table 25 North America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
• Table 26 North America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
• Table 27 North America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
• Table 28 North America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
• Table 29 North America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
• Table 30 North America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 31 North America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 32 North America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
• Table 33 North America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
• Table 34 North America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
• Table 35 North America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 36 North America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 37 North America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 38 North America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 39 Europe Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 41 Europe Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
• Table 42 Europe Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
• Table 43 Europe Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
• Table 44 Europe Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
• Table 45 Europe Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
• Table 46 Europe Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
• Table 47 Europe Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
• Table 48 Europe Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
• Table 49 Europe Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 50 Europe Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 51 Europe Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
• Table 52 Europe Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
• Table 53 Europe Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
• Table 54 Europe Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 55 Europe Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 56 Europe Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 57 Europe Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 58 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 60 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
• Table 61 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
• Table 62 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
• Table 63 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
• Table 64 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
• Table 65 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
• Table 66 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
• Table 67 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
• Table 68 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 69 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 70 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
• Table 71 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
• Table 72 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
• Table 73 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 74 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 75 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 76 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 77 South America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 79 South America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
• Table 80 South America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
• Table 81 South America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
• Table 82 South America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
• Table 83 South America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
• Table 84 South America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
• Table 85 South America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
• Table 86 South America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
• Table 87 South America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 88 South America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 89 South America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
• Table 90 South America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
• Table 91 South America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
• Table 92 South America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 93 South America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 94 South America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 95 South America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 96 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 98 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
• Table 99 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
• Table 100 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
• Table 101 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
• Table 102 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
• Table 103 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
• Table 104 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
• Table 105 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
• Table 106 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 107 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 108 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
• Table 109 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
• Table 110 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
• Table 111 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 112 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 113 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 114 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)

According to Stratistics MRC, the Global Erectile Dysfunction Drugs Market is accounted for $2.83 billion in 2023 and is expected to reach $5.11 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Erectile dysfunction (ED) drugs are medications designed to treat the inability to achieve or maintain an erection sufficient for sexual intercourse. They work by increasing blood flow to the penis, facilitating an erection when sexually stimulated. Common ED drugs include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), which belong to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. These drugs are typically taken orally and have revolutionized the treatment of ED, offering millions of men a reliable and effective solution to enhance their sexual performance and quality of life.

According to the Clinical Epidemiology and Global Health Journal, Erectile Dysfunction affects more than 150 million men globally, and by 2025, that number is predicted to rise to 322 million. According to the National Institutes of Health (NIH), in 2022, erectile dysfunction (ED) is very common condition in U.S. It affects about 30 million men in the U.S. every year.

Market Dynamics:

Driver:

Growing awareness and acceptance

The growing awareness and acceptance of ED drugs in the erectile dysfunction market signifies the increasing recognition and normalization of ED as a medical condition. As societal attitudes evolve and conversations around sexual health become more open, individuals are more likely to seek treatment for ED. This shift in perception leads to greater acceptance of ED drugs as legitimate solutions, boosting their demand. Additionally, education campaigns and advertising efforts play a crucial role in spreading awareness about available treatment options, further fueling market growth.

Restraint:

Regulatory hurdles

Regulatory hurdles in the erectile dysfunction drug market primarily stem from stringent approval processes and ongoing monitoring by health authorities. These hurdles include rigorous clinical trials to establish safety and efficacy, as well as compliance with labeling and advertising regulations. Additionally, concerns over potential side effects and interactions with other medications contribute to the regulatory complexity. Market entry may also be delayed by patent protections and intellectual property disputes. Navigating these regulatory hurdles demands substantial resources and expertise, which can restrain competition and innovation in the ED drug market.

Opportunity:

Innovation in drug development

The innovation in drug development within the erectile dysfunction market presents a promising opportunity for both pharmaceutical companies and patients. With advancements in understanding the underlying causes of ED, such as vascular issues, neurological disorders, and hormonal imbalances, researchers can target novel pathways for drug interventions. This innovation could lead to more effective and safer treatment options, potentially with fewer side effects compared to current medications like Viagra and Cialis. Furthermore, breakthroughs in personalized medicine may enable tailored treatments based on individual patient characteristics, enhancing efficacy and patient satisfaction.

Threat:

Patent expiry

The patent expiry threat in the Erectile Dysfunction drugs market refers to the looming loss of exclusivity for major medications like Viagra, Cialis, and Levitra. As these patents expire, generic versions can enter the market, leading to intense competition and price erosion for the original brands. This could significantly impact revenue streams for pharmaceutical companies that have held exclusive rights to these drugs. Moreover, generic alternatives often come at lower prices, enticing consumers away from branded products. This scenario poses a challenge for companies to maintain market share and profitability in the face of increased competition.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the erectile dysfunction (ED) drug market. With restrictions on movement and healthcare priorities shifting towards managing the pandemic, the demand for ED drugs saw fluctuations. While initial lockdowns led to a decrease in doctor visits and prescriptions, there was a subsequent rise in demand as restrictions eased and telemedicine became more prevalent. Due to house restrictions, there was a substantial growth of intimate activities among newlywed couples and others, which consequently led to growth of several things related to intercourse including ED drugs. Economic uncertainties also influenced consumer spending on non-essential medications like ED drugs.

The viagra (sildenafil citrate) segment is expected to be the largest during the forecast period

The growth of the Viagra (Sildenafil Citrate) segment in the ED drug market can be attributed to several factors. Viagra was one of the pioneering drugs in ED treatment, establishing a strong brand presence and trust among consumers. Its efficacy in treating ED is well-established, leading to widespread adoption by physicians and patients alike. The availability of generic versions of Sildenafil Citrate has increased affordability and accessibility, further fueling market growth. Moreover, continuous research and development efforts have resulted in innovative formulations and delivery methods, expanding the market reach. Furthermore, increasing awareness about ED and the destigmatization of seeking treatment have contributed to the overall expansion of the ED drug market, with Viagra leading the charge.

The topical medications segment is expected to have the highest CAGR during the forecast period

The growth in the topical medication segment can be attributed to the convenience and discretion offered by topical formulations, appealing to consumers seeking non-invasive treatment options. Advancements in formulation technology have improved the efficacy and absorption rates of topical medications, enhancing their effectiveness. The growing awareness and acceptance of topical treatments among both patients and healthcare providers have fuelled market demand. Additionally, the preference for localized treatment with fewer systemic side effects has bolstered the adoption of topical medications, contributing to the segment's sustained expansion.

Region with largest share:

The North American region has experienced significant growth in the erectile dysfunction drug market due to increasing awareness about ED and its growing treatment options. Advancements in medical technology have led to the development of more effective and safer ED drugs, boosting consumer confidence and uptake. Additionally, the aging population in North America, coupled with lifestyle factors such as stress and sedentary habits, has contributed to the rise in ED cases, thus driving the demand for treatment. Robust healthcare infrastructure and favourable reimbursement policies in the region have facilitated access to ED drugs, further fuelling market growth.

Region with highest CAGR:

The Asia-Pacific region has witnessed a notable surge due to several factors. Increasing awareness about sexual health, the rising incidence of lifestyle-related disorders, and expanding access to healthcare services are key drivers. Furthermore, cultural shifts towards more open discussions about sexual health have reduced stigma, encouraging individuals to seek treatment. Furthermore, the availability of innovative treatment options has fuelled market growth. With a large population base and improving healthcare infrastructure, the Asia-Pacific region presents significant opportunities for further expansion in the erectile dysfunction drug market.

Key players in the market

Some of the key players in Erectile Dysfunction Drugs market include Abbott Laboratories, Allergan plc, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co., Ltd., Eli Lilly and Company, Endo International plc, Futura Medical plc, Ion Channel Innovations, LLC, Johnson & Johnson, Meda Pharmaceuticals Inc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., Regent Pacific Group Limited, Sandoz International GmbH, Sinil Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Ltd. and VIVUS, Inc.

Key Developments:

In March 2024, Johnson & Johnson's JNJ wholly-owned subsidiary, Johnson & Johnson MedTech, recently announced its partnership with Nvidia to accelerate secure, real-time analysis of surgical data using artificial intelligence (AI). The two businesses collaborated to enable more global availability of AI algorithms and real-time analytical access. Their goal is to have an impact on surgical decision-making, teamwork, and education in all linked operating rooms (ORs).

In January 2024, Glenmark said it has partnered with Pfizer to launch abrocitinib in India used for treatment of moderate-to-severe atopic dermatitis (AD). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO).

Drug Types Covered:

• Viagra (Sildenafil Citrate)
• Avanafil (Stendra/Spedra)
• Cialis (Tadalafil)
• Helleva (Lodenafil Carbonate)
• Levitra/Staxyn (Vardenafil)
• Mvix (Mirodenafil)
• Vitaros (Alprostadil)
• Zydena (Udenafil)
• Other Drug Types

Route of Administrations Covered:

• Oral Medications
• Topical Medications
• Injections

Distribution Channels Covered:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Erectile Dysfunction Drugs Market, By Drug Type

• 5.1 Introduction
• 5.2 Viagra (Sildenafil Citrate)
• 5.3 Avanafil (Stendra/Spedra)
• 5.4 Cialis (Tadalafil)
• 5.5 Helleva (Lodenafil Carbonate)
• 5.6 Levitra/Staxyn (Vardenafil)
• 5.7 Mvix (Mirodenafil)
• 5.8 Vitaros (Alprostadil)
• 5.9 Zydena (Udenafil)
• 5.10 Other Drug Types

6 Global Erectile Dysfunction Drugs Market, By Route of Administration

• 6.1 Introduction
• 6.2 Oral Medications
• 6.3 Topical Medications
• 6.4 Injections

7 Global Erectile Dysfunction Drugs Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Pharmacies
• 7.4 Retail Pharmacies

8 Global Erectile Dysfunction Drugs Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Allergan plc
• 10.3 Apricus Biosciences, Inc.
• 10.4 Bayer AG
• 10.5 Cristalia Produtos Quimicos Farmaceuticos Ltda.
• 10.6 Dong-A Pharmaceutical Co., Ltd.
• 10.7 Eli Lilly and Company
• 10.8 Endo International plc
• 10.9 Futura Medical plc
• 10.10 Ion Channel Innovations, LLC
• 10.11 Johnson & Johnson
• 10.12 Meda Pharmaceuticals Inc.
• 10.13 Metuchen Pharmaceuticals, LLC
• 10.14 Pfizer Inc.
• 10.15 Regent Pacific Group Limited
• 10.16 Sandoz International GmbH
• 10.17 Sinil Pharmaceutical Co., Ltd.
• 10.18 SK Chemicals Co., Ltd.
• 10.19 Teva Pharmaceutical Industries Ltd.
• 10.20 VIVUS, Inc.